NCT07545603 2026-04-22
Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma
Evopoint Biosciences Inc.
Phase 2 Recruiting
Clinical Trials
106 trialsNCT06745583 2026-04-09
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Phase 2 Recruiting
NCT05962606 2026-03-18
Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.
Aptarion Biotech AG
Phase 2 Completed
NCT05458297 2026-03-12
MK-2140-006
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT05023018 2026-03-02
NEO100 and High-Grade Meningioma
Neonc Technologies, Inc.
Phase 2 Recruiting
NCT06526793 2026-02-25
SOUNDTRACK-B
AstraZeneca
Phase 2 Recruiting
NCT03332017 2026-02-18
ROSEWOOD
BeOne Medicines
Phase 2 Completed
NCT05926765 2026-02-02
AQUAx2
MeiraGTx UK II Ltd
Phase 2 Recruiting
NCT06068881 2026-01-30
Mandolin
Ipsen
Phase 2 Withdrawn
NCT07360288 2026-01-22
TC011_FL_201
TICAROS Co., Ltd.
Phase 2 Not yet recruiting
NCT06425302 2026-01-08
GOLSEEK-2
Celgene
Phase 2 Active not recruiting
NCT03105336 2025-12-23
ZUMA-5
Gilead Sciences
Phase 2 Completed
NCT05020652 2025-12-17
A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Active not recruiting
NCT03774082 2025-12-11
REACH 5
Novartis
Phase 2 Completed
NCT04245839 2025-11-05
TRANSCEND FL
Celgene
Phase 2 Active not recruiting
NCT06544798 2025-10-16
Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia
MeiraGTx UK II Ltd
Phase 2 Enrolling by invitation
NCT03888105 2025-10-15
ELM-2
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT03568461 2025-10-07
ELARA
Novartis
Phase 2 Completed
NCT05951777 2025-09-29
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
Hope Biosciences Research Foundation
Phase 2 Recruiting
NCT05785715 2025-07-01
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
AbbVie
Phase 2 Terminated
NCT03600441 2025-04-10
FORERUNNER
Xynomic Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT03934567 2025-04-10
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Xynomic Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT04849351 2025-04-06
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Hutchmed
Phase 2 Completed
NCT03126019 2025-03-14
CITADEL-203
Incyte Corporation
Phase 2 Completed
NCT02413489 2025-02-04
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Janssen Research & Development, LLC
Phase 2 Terminated
NCT04305444 2025-01-08
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Phase 2 Terminated
NCT03768505 2024-12-31
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
MEI Pharma, Inc.
Phase 2 Terminated
NCT05008055 2024-12-20
CAPITAL
AstraZeneca
Phase 2 Completed
NCT00597909 2024-12-17
Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
Amgen
Phase 2 Terminated
NCT05156125 2024-11-13
VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
Oppilan Pharma Ltd
Phase 2 Active not recruiting
NCT03520920 2024-10-26
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
BeiGene
Phase 2 Completed
NCT04434937 2024-10-23
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
Incyte Corporation
Phase 2 Completed
NCT03610724 2024-06-20
BIANCA
Novartis
Phase 2 Completed
NCT04298879 2024-06-05
IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Completed
NCT06368167 2024-04-16
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Not yet recruiting
NCT04762160 2024-03-25
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Ipsen
Phase 2 Terminated
NCT05125562 2024-02-13
Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19
Direct Biologics, LLC
Phase 2 Withdrawn
NCT04358406 2023-11-28
Rhu-pGSN for Severe Covid-19 Pneumonia
BioAegis Therapeutics Inc.
Phase 2 Completed
NCT04089215 2023-11-24
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2 Unknown
NCT04699461 2023-10-23
LOTIS-6
ADC Therapeutics S.A.
Phase 2 Terminated
NCT00081809 2023-09-28
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
Agenus Inc.
Phase 2 Completed
NCT03982225 2023-08-15
AYP-101
AMIpharm Co., Ltd.
Phase 2 Completed
NCT05266729 2023-08-15
Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area
AMIpharm Co., Ltd.
Phase 2 Completed
NCT05222516 2023-08-08
Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD
OM Pharma SA
Phase 2 Terminated
NCT03828448 2023-07-24
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
TG Therapeutics, Inc.
Phase 2 Terminated
NCT04733833 2023-02-01
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase 2 Completed
NCT03456726 2022-12-16
Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
Eisai Inc.
Phase 2 Completed
NCT05371275 2022-11-07
CDK6COV
biotx.ai GmbH
Phase 2 Withdrawn
NCT03738423 2022-06-10
Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Regeneron Pharmaceuticals
Phase 2 Terminated
NCT03736967 2021-11-01
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Regeneron Pharmaceuticals
Phase 2 Terminated